Advertisement

Aspirin attenuates podocyte injury in diabetic rats through overriding cyclooxygenase-2-mediated dysregulation of LDL receptor pathway

  • Kun Ling Ma
  • Liang Liu
  • Yang Zhang
  • Gui Hua Wang
  • Ze Bo Hu
  • Pei Pei Chen
  • Jian Lu
  • Chen Chen Lu
  • Tie Kai Gong
  • Yu Xiang Gong
  • Bi Cheng Liu
Nephrology - Original Paper
  • 20 Downloads

Abstract

Aim

This study aimed to investigate the effects of aspirin on podocyte injury and its underlying mechanisms in diabetic nephropathy (DN).

Methods

Eight-week-old male Sprague–Dawley rats were divided into three groups: non-diabetic rats (Control), streptozotocin-induced diabetic rats (DM), and diabetic rats treated with aspirin (DM + Aspirin) for 12 weeks. Intracellular lipid accumulation was evaluated by Oil Red O staining and quantitative free cholesterol assays. Podocyte injury and the levels of COX-2, inflammatory cytokines, and low-density lipoprotein receptor (LDLr) pathway-related proteins were evaluated by electron microscopy, immunohistochemical staining, and Western blotting, respectively.

Results

Lipid levels and urinary albumin–creatinine ratios were higher in the DM rats than in the Control rats. Periodic acid-Schiff staining showed glomerular hypertrophy and mild mesangial area widening in the DM rats. Electron microscopy showed that the podocyte foot processes were significantly flattened or absent in the DM rats. The protein expression levels of WT-1 and nephrin in the podocytes of DM rats were reduced. Interestingly, lipid accumulation in the kidneys of DM rats was significantly increased due to increased protein expression levels of LDLr, sterol regulatory element-binding protein (SREBP) cleavage-activating protein (SCAP), SREBP-2, cyclooxygenase-2 (COX-2), and inflammatory cytokines. Confocal immunofluorescent staining showed that COX-2 and WT-1 were co-expressed. Furthermore, COX-2 protein expression levels were positively correlated with LDLr protein expression levels. However, when COX-2 expression was inhibited by aspirin, these changes in the DM rats were significantly attenuated.

Conclusion

Aspirin attenuates podocyte injury in DN, which may be through COX-2-mediated dysregulation of LDLr pathway.

Keywords

Aspirin Cyclooxygenase-2 LDL receptor Podocyte injury Diabetic nephropathy 

Notes

Funding

This work was supported by the National Natural Science Foundation of China (Grant 81470957), the Jiangsu Province Social Development Project (BE2018744), the Project for Jiangsu Provincial Medical Talent (ZDRCA2016077), the Jiangsu Province Six Talent Peaks Project (2015-WSN-002), the Fundamental Research Funds for the Central Universities (KYCX18-0182, KYCX17-0169, KYZZ15-0061), the Jiangsu Province Ordinary University Graduate Research Innovation Project (SJZZ16-004), and the Project of Nanjing Municipal Committee for Health and Family Planning (YKK17280).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Chen J, Cui W, Zhang Q, Jia Y, Sun Y, Weng L et al (2015) Low molecular weight fucoidan ameliorates diabetic nephropathy via inhibiting epithelial-mesenchymal transition and fibrotic processes. Am J Transl Res 7(9):1553–1563PubMedPubMedCentralGoogle Scholar
  2. 2.
    Chen HC, Guh JY, Chang JM, Hsieh MC, Shin SJ, Lai YH (2005) Role of lipid control in diabetic nephropathy. Kidney Int 67(Suppl 94):S60–S62Google Scholar
  3. 3.
    Zhang Y, Ma KL, Ruan XZ, Liu BC (2016) Dysregulation of the low-density lipoprotein receptor pathway is involved in lipid disorder-mediated organ injury. Int J Biol Sci 12(5):569–579CrossRefGoogle Scholar
  4. 4.
    Hao CM, Breyer MD (2007) Physiologic and pathophysiologic roles of lipid mediators in the kidney. Kidney Int 71(11):1105–1115CrossRefGoogle Scholar
  5. 5.
    Komers R, Lindsley JN, Oyama TT, Schutzer WE, Reed JF, Mader SL et al (2001) Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 107(7):889–898CrossRefGoogle Scholar
  6. 6.
    Jia Z, Zhang Y, Ding G, Heiney KM, Huang S, Zhang A (2015) Role of COX-2/mPGES-1/prostaglandin E2 cascade in kidney injury. Mediators Inflamm.  https://doi.org/10.1155/2015/147894 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Park YG, Kang SK, Noh SH, Park KK, Chang YC, Lee YC et al (2004) PGE2 induces IL-1beta gene expression in mouse osteoblasts through a cAMP-PKA signaling pathway. Int Immunopharmacol 4(6):779–789CrossRefGoogle Scholar
  8. 8.
    Sugimoto Y, Inazumi T, Tsuchiya S (2015) Roles of prostaglandin receptors in female reproduction. J Biochem 157(2):73–80CrossRefGoogle Scholar
  9. 9.
    Cheng H, Wang S, Jo YI, Hao CM, Zhang M, Fan X et al (2007) Overexpression of cyclooxygenase-2 predisposes to podocyte injury. J Am Soc Nephrol 18(2):551–559CrossRefGoogle Scholar
  10. 10.
    Cheng H, Fan X, Guan Y, Moeckel GW, Zent R, Harris RC (2009) Distinct roles for basal and induced COX-2 in podocyte injury. J Am Soc Nephrol 20(9):1953–1962CrossRefGoogle Scholar
  11. 11.
    Cheng H, Fan X, Moeckel GW, Harris RC (2011) Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression. J Am Soc Nephrol 22(7):1240–1251CrossRefGoogle Scholar
  12. 12.
    Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, Harris RC (2002) Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 62(3):929–939CrossRefGoogle Scholar
  13. 13.
    Quilley J, Santos M, Pedraza P (2011) Renal protective effect of chronic inhibition of COX-2 with SC-58236 in streptozotocin-diabetic rats. Am J Physiol Heart Circ Physiol 300(6):H2316–H2322CrossRefGoogle Scholar
  14. 14.
    Wang JL, Cheng HF, Shappell S, Harris RC (2000) A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 57(6):2334–2342CrossRefGoogle Scholar
  15. 15.
    Zhang Y, Ma KL, Liu J, Wu Y, Hu ZB, Liu L et al (2015) Dysregulation of low-density lipoprotein receptor contributes to podocyte injuries in diabetic nephropathy. Am J Physiol Endocrinol Metab 308(12):E1140–E1148CrossRefGoogle Scholar
  16. 16.
    Duran-Salgado MB, Rubio-Guerra AF (2014) Diabetic nephropathy and inflammation. World J Diabetes 5(3):393–398CrossRefGoogle Scholar
  17. 17.
    Lim AK, Tesch GH (2012) Inflammation in diabetic nephropathy. Mediators Inflamm.  https://doi.org/10.1155/2012/146154 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Kanasaki K, Taduri G, Koya D (2013) Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis. Front Endocrinol (Lausanne) 4:7CrossRefGoogle Scholar
  19. 19.
    Wada J, Makino H (2013) Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond) 124(3):139–152CrossRefGoogle Scholar
  20. 20.
    Srivastava SP, Shi S, Koya D, Kanasaki K (2014) Lipid mediators in diabetic nephropathy. Fibrogenesis Tissue Repair 7:12CrossRefGoogle Scholar
  21. 21.
    Taskinen MR (2005) Type 2 diabetes as a lipid disorder. Curr Mol Med 5(3):297–308CrossRefGoogle Scholar
  22. 22.
    Hirano T (2014) Abnormal lipoprotein metabolism in diabetic nephropathy. Clin Exp Nephrol 18(2):206–209CrossRefGoogle Scholar
  23. 23.
    Joles JA, Kunter U, Janssen U, Kriz W, Rabelink TJ, Koomans HA et al (2000) Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol 11(4):669–683PubMedGoogle Scholar
  24. 24.
    Ruan XZ, Varghese Z, Moorhead JF (2003) Inflammation modifies lipid-mediated renal injury. Nephrol Dial Transpl 18(1):27–32CrossRefGoogle Scholar
  25. 25.
    Zhang Y, Ma KL, Liu J, Wu Y, Hu ZB, Liu L et al (2015) Inflammatory stress exacerbates lipid accumulation and podocyte injuries in diabetic nephropathy. Acta Diabetol 52(6):1045–1056CrossRefGoogle Scholar
  26. 26.
    Alhouayek M, Muccioli GG (2014) COX-2-derived endocannabinoid metabolites as novel inflammatory mediators. Trends Pharmacol Sci 35(6):284–292CrossRefGoogle Scholar
  27. 27.
    Rajakariar R, Yaqoob MM, Gilroy DW (2006) COX-2 in inflammation and resolution. Mol Interv 6(4):199–207CrossRefGoogle Scholar
  28. 28.
    Goldstein SL, Leung JC, Silverstein DM (2006) Pro- and anti-inflammatory cytokines in chronic pediatric dialysis patients: effect of aspirin. Clin J Am Soc Nephrol 1(5):979–986CrossRefGoogle Scholar
  29. 29.
    Donadio JV Jr, Ilstrup DM, Holley KE, Romero JC (1988) Platelet-inhibitor treatment of diabetic nephropathy: a 10-year prospective study. Mayo Clin Proc 63(1):3–15CrossRefGoogle Scholar
  30. 30.
    Khajehdehi P, Roozbeh J, Mostafavi H (2002) A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scand J Urol Nephrol 36:145–148CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Institute of Nephrology, Zhong Da HospitalMedical School of Southeast UniversityNang JingChina

Personalised recommendations